Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
Naval Daver, MD / Joseph D. Khoury, MD, FCAP - The Pathology–Oncology Partnership in AML: Identifying and Treating the Diversity of Disease Subtypes
Manage episode 277422486 series 103590
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/PDK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist-oncologist panel discusses how modern, team-based treatment decisions are guided by the results of molecular/pathology testing across a wide range of acute myeloid leukemia (AML) settings, while also profiling how new evidence influences pathologic assessment and treatment selection across the continuum of AML care. Upon completion of this activity, participants should be better able to: Identify specific molecular and histopathologic features that can inform the diagnosis of different AML subtypes, including secondary AML/AML-MRC or FLT3- or IDH-mutant AML, Select appropriate evidence-based molecular/pathology tests to confirm a diagnosis of AML, Develop molecular testing strategies to collect relevant information over the course of the AML treatment continuum, Recommend appropriate, safe management options for patients with diverse AML subtypes in collaboration with the wider oncology management team.